2 december 2017: klik op de titel:

Patients with a newly diagnosed glioblastoma multiforme (GBM) brain tumor may now enroll in a Phase 1b/2a clinical trial testing a triple immunotherapy combination for the cancer.

Inovio Pharmaceuticals is leading the study to evaluate its T-cell activating therapies INO-5401 and INO-9012 in combination with cemiplimab, a PD-1 inhibitor developed by Regeneron Pharmaceuticals.

INO-5401 is an immunotherapy that encodes the antigens for the WT1, hTERT, and PSMA proteins found at high levels in several cancer cell types, but minimally expressed in healthy tissues.

Due to their specificity, these proteins have been designated by the National Cancer Institute as high priorities for cancer immunotherapy development.

While INO-5401 encodes for cancer proteins, INO-9012 encodes for the interleukin-12 (IL-12) protein, which triggers the activation and expansion of immune T-cells, boosting the anti-cancer immune response.

Cemiplimab, formerly known as REGN2810, is an anti-PD-1 immune checkpoint inhibitor developed by Regeneron and Sanofi. It is also used to boost the immune activity against tumor cells.


Plaats een reactie ...

Reageer op "Inovio Pharmaceuticals Initiates Immuno-Oncology Clinical Study for Glioblastoma in Combination with Regeneron’s PD-1 Inhibitor"


Gerelateerde artikelen